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http://dx.doi.org/10.1016/j.jmii.2015
1684-1182/Copyright ª 2015, TaiwanBackground: Acinetobacter baumannii is one of the most important noscomial pathogens
worldwide. The study aimed to use multilocus sequence typing (MLST) for epidemiological sur-
veillance of A. baumannii isolates in Taiwan and analyze the clinical presentations and pa-
tients’ outcomes.
Methods: MLST according to both Bartual’s PubMLST and Pasteur’s MLST schemes was applied
to characterize bloodstream imipenem-resistant A. baumannii (IRAB) infection in intensive
care units in a medical center. A total of 39 clinical IRAB bloodstream isolates in 2010 were
enrolled. We also collected 13 imipenem-susceptible A. baumannii bloodstream isolates and
30 clinical sputum isolates (24 IRAB and 6 imipenem-susceptible A. baumannii) for comparison.
Clinical presentations and outcome of the patients were analyzed.
Results: We found that infection by ST455B/ST2P and inappropriate initial therapy were statis-
tically significant risk factors for mortality. More than one third of the IRAB isolates belonged to
ST455B/ST2P. Most ST455B/ST2P (80%) carried ISAba1eblaOXA-23, including 10 (66.7%) with
Tn2006 (ISAba1eblaOXA-23eISAba1) in an AbaR4-type resistance island. ST455
B/ST2P appears
to evolve from ST208B/ST2P of clonal complex (CC) 92B/CC2P. In this hospital-based study,
A. baumannii ST455 accounted for 38.5% of IRAB bacteremia, with a high mortality of 86.7%.ediatric Infectious Diseases, Department of Pediatrics, Chang Gung Children’s Hospital, No. 5, Fu-Hsin
n.
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j.jmii.2015.04.001Approximately 85% of ST455B/ST2P bacteremia had a primary source of ventilation-associated
pneumonia.
Conclusion: We report the emergence in Taiwan of IRAB ST455B/ST2P, which is the current pre-
dominant clone of IRAB in our hospital and has been causing bacteremia with high mortality in
critical patients.
Copyright ª 2015, Taiwan Society of Microbiology. Published by Elsevier Taiwan LLC. All rights
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Acinetobacter baumannii is one of the most important
noscomial pathogens worldwide, causing bacteremia,
pneumonia, urinary tract infection, soft tissue infection, or
intra-abdominal infection in hospitalized patients.1
Bacteremia caused by imipenem-resistant A. baumannii
(IRAB) has been associated with a higher mortality (46.0%)
than bacteremia by imipenem-susceptible A. baumannii
(ISAB; 28.3%) and other diagnoses of A. baumannii infec-
tion.2 The most common source of A. baumannii infection
was the respiratory tract,1 however, the relationship be-
tween respiratory tract infection and IRAB bacteremia re-
mains unknown.
Multilocus sequence typing (MLST) is a widely used
technique for bacterial typing, proven to provide unam-
biguous typing data for long-term and global A. baumannii
epidemiological surveillance.3 Two MLST schemes, Bartual’s
PubMLST and Pasteur’s MLST, are available in delineating
the population structure of A. baumannii.3e6 However,
there are no published Bartual’s MLST data in clinical A.
baumannii isolates in Taiwan.
This study using MLST was designed to characterize
bloodstream IRAB infection of intensive care unit (ICU)
patients in 2010 in a single medical center. We compared
the result with those from bloodstream ISAB, and also IRAB
and ISAB from sputum of patients with clinically confirmed
ventilation-associated pneumonia (VAP).
Materials and methods
Study patients and inclusion criteria
This study was approved by the Institutional Review Board
(100-3592B) of Chang Gung Memorial Hospital (CGMH),
Taiwan. Charts were reviewed for ICU patients who were
treated in CGMH in 2010 and had VAP, at least one positive
blood or sputum culture for A. baumannii, and symptoms
and signs of infection. For patients with multiple episodes,
only the first episode was included. Patients with incom-
plete medical records, aged < 18 years, or with poly-
microbial infection were excluded.
Clinical data collection and definitions
Clinical data were collected retrospectively. VAP was
defined as pneumonia with pulmonary infiltrates on chest
radiographs, purulent tracheal secretions not less than 48ee H-Y, et al., Emergence in Tai
ical patients, Journal of Microbiolhours after intubation, and the start of mechanical venti-
lation.7,8 VAP as a primary source was defined by the con-
dition when at least one A. baumannii sputum isolate was
found from patients with VAP before the development of
bacteremia, which was proved by the isolation of an A.
baumannii in blood. Mortality was defined as infection-
attributable death, wherein the criteria of death were
met before the symptoms and signs of bacteremia or
pneumonia were resolved, and with at least a blood or
sputum culture positive for A. baumannii.9 Appropriate
antimicrobial therapy was defined as administering patients
with at least one antimicrobial agent, except aminoglyco-
side, susceptible in vitro, within 2 days after bacteremia
onset.10 Culture detecting time was the interval (days)
from culture sampling to reporting.
Bacterial isolates and antimicrobial susceptibility
Conventional biochemical tests and 16Se23S rRNA inter-
genic spacer region sequencing as described previously
were used to characterize bacterial genospecies.11 Anti-
microbial susceptibility was determined by the disk diffu-
sion method according to Clinical and Laboratory Standards
Institute standards.12 Minimum inhibitory concentration
(MIC) of imipenem was further determined using Etest
(Biome`rieux, La Balmes les Grottes, France). The break-
point for defining ISAB was an MIC  4 mg/L, and a break-
point of  8 mg/L for IRAB, including both intermediately-
resistant and resistant strains.12 The tigecycline disk
diffusion breakpoints were based on the FDA criteria (sus-
ceptible:  16 mm; resistant:  12 mm).13
MLST
In order to survey clonal relationships, Bartual’s PubMLST
and Pasteur’s MLST schemes were used.4,5 By Bartual’s
PubMLST method, seven standard housekeeping loci [cit-
rate synthase (gltA), gyrase B (gyrB), glucose dehydroge-
nase B (gdhB), recombination A (recA), chaperone 60
(cpn60), glucose-6-phosphate isomerase (gpi), and RNA
polymerase (rpoD)] were checked.4 Sequences were
compared with the A. baumannii database at the MLST
database (http://pubmlst.org/abaumannii/) and conduct-
ed by the Basic Local Alignment Search Tool (BLAST, Na-
tional Library of Medicine, Bethesda, MD 20894, USA). By
the Pasteur’s MLST scheme (www.pasteur.fr/recherche/
genopole/PF8/mlst/Abaumannii.html), internal fragments
of seven housekeeping genes [cpn60, protein elongation
factor EF-G (fusA), gltA, CTP synthase (pyrG), recA, 50Swan of novel imipenem-resistant Acinetobacter baumannii ST455
ogy, Immunology and Infection (2015), http://dx.doi.org/10.1016/
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(rpoB)] were amplified and sequenced for each isolate.5
The eBURST algorithm (http://eburst.mlst.net/) was
used to analyze the genetic relationships of sequence types
(STs).14 Clonal complexes (CCs) were stringently defined as
a cluster of STs having the same alleles at six of the seven
loci and containing at least two STs.14 Novel CCs were
named by the STs of their founders.
Pulsed-field gel electrophoresis
Isolates were analyzed by pulsed-field gel electrophoresis
(PFGE) using methods as described elsewhere.15 The frag-
ment patterns obtained were interpreted as described by
Tenover et al.16 Briefly, isolates with no less than seven-
band difference were considered to be different geno-
types, which were arbitrarily designated in alphabetical
order. Isolates with identical fingerprints and less than two-
band difference were considered as the same genotype,
whereas those with two-band to six-band difference were
considered subtypes of an existing genotype.
Polymerase chain reaction and sequencing
Primers specific for imipenem resistance genes (blaOXA-23,
blaOXA-40, blaOXA-54, blaOXA-58, blaOXA-51, blaADC, blaIMP-1,
blaIMP-2, blaVIM-1, blaVIM-2, and blaNDM-1), insertion se-
quences (ISAba1, ISAba2, ISAba3, ISAba4 and IS1008), and
the AbaR4-type islands were designed, and polymerase
chain reaction amplification and sequence determination
were performed as described previously.17e19
Statistical analysis
Data analyses were performed using SPSS software, v. 17.0
(SPSS Inc., Chicago, IL, USA). Student t test, Chi-square
test, or Fisher exact test were used when appropriate to
compare proportions. Variables with a p value < 0.2 in the
univariate analysis were added in a forward stepwise
manner and selected to create the final model for multi-
variable analysis. All statistical analyses were two-sided,
and significance was set at p < 0.05.
Results
Clinical isolates
A total of 39 clinical IRAB bloodstream isolates in 2010 met
the inclusion criteria and were enrolled in this cohort study
(Table 1). For comparison, we collected 13 ISAB blood-
stream isolates and 30 clinical sputum isolates (24 IRAB and
6 ISAB) from patients who were treated in the same year
and also met the inclusion criteria (Tables 1 and 2).
Sequence types, antimicrobial susceptibilities, and
PFGE genotypes
There were 26 novel STs according to Bartual’s PubMLST
scheme in this study, including ST455, ST456, ST544 to
ST556, and ST673 to ST683. These novel STs were newlyPlease cite this article in press as: Lee H-Y, et al., Emergence in Tai
causing bloodstream infection in critical patients, Journal of Microbiolo
j.jmii.2015.04.001found in Chang Gung Memorial Hospital in Taiwan, and
registered in the PubMLST web site (http://pubmlst.org/).
Most IRAB isolates (38.5% from bloodstream and 45.8%
sputum) belonged to ST455. ST455 isolates were suscepti-
ble to colistin (100%), and tigecycline (66.7%), but were
86.7% resistant to ampicillinesulbactam and 100% resistant
to all other antibiotics tested.
Most IRAB isolates belonged to CC92 and CC455 (blood-
stream, CC455 48.7%, CC92 28.2%, and sputum, CC455
62.5%, CC92 20.8%). In contrast to IRAB, few ISAB isolates
(15.4% from bloodstream and 16.7% sputum) belonged to
CC92 and no ISAB was in CC455. STs of ISAB were so diverse
that 13 bloodstream isolates belonged to 11 different STs
and six sputum isolates belonged to six different STs.
No difference was found in the ratio of ST455 among
IRAB isolated from blood and sputum (15/39 vs. 11/24,
p Z 0.564). Similar results were also found in all other STs
(all p > 0.05).
More than half of the IRAB clinical isolates were found in
the main evolutionary tract of CC92 to the novel CC455,
descending from the founder ST208 to ST544, and then to
ST455 (Figure 1). It is notable that the attributable mor-
tality in patients infected by these STs appeared higher and
higher along the evolution (ST208: 33.3%; ST544: 75%;
ST455: 86.7%) but this should be evaluated further. ST544 is
a one-locus variant of ST455 and two-locus variant of ST92
(1-3-3-2-2-7-3). ST544 therefore belonged to CC455 but not
CC92.
By contrast, among 39 IRAB isolates, 34 isolates (87.2%)
belonged to ST2, three (7.7%) to ST129, one (2.6%) to
ST217, and one (2.6%) novel STN1 (Table 1) according to
Pasteur’s MLST scheme.
Based on Tenover et al’s16 criteria, the 39 bloodstream
IRAB isolates included 15 different PFGE genotypes and
their subtypes. Sixty percent (9/15) ST455B and 50% (17/34)
ST2P belonged to PFGE genotype 1 or its seven subtypes.Imipenem resistance genes
All isolates carried blaOXA-51-like. The blaOXA-23 gene (Gen-
Bank accession No. GQ861439.1) was found in 54 isolates
(65.9%, 54/82). The blaOXA-58 gene appeared in three
isolates.
Among the 39 bloodstream IRAB isolates, the upstream
ISAba1 was found in seven (17.9%) with blaOXA-51-like and in
25 (64.1%) with blaOXA-23, including 18 with Tn2006 (ISA-
ba1eblaOXA-23eISAba1) in an AbaR4-type resistance island
and seven with Tn2008 (ISAba1eblaOXA-23) (Table 1). All of
these isolates showed high-level resistance to imipenem
(all MIC > 32 mg/L). Two isolates (ST455 and ST208) carried
blaIMP-1. None carried blaOXA-40/blaOXA-24, blaIMP-2, blaVIM-1,
blaVIM-2, blaNDM-1, blaADC, ISAba2, IS1008, or Tn2007 (ISA-
ba4eblaOXA-23).
Among the 24 IRAB isolates from sputum, the upstream
ISAba1 was found in two isolates (8.3%) with blaOXA-51-like
and in 20 (83.3%) with blaOXA-23, including 18 Tn2006 (ISA-
ba1eblaOXA-23eISAba1) in an AbaR4-type resistance island
and two Tn2008 (ISAba1eblaOXA-23) (Table 2). All of these
isolates showed high-level resistance to imipenem (all
MIC > 32 mg/L). Tn2007 (ISAba4eblaOXA-23) was not found
in these isolates. The upstream ISAba3 was found in onewan of novel imipenem-resistant Acinetobacter baumannii ST455
gy, Immunology and Infection (2015), http://dx.doi.org/10.1016/
Table 1 Sequence types (ST), allelic profiles, clonal complex (CC), imipenem resistance genes, primary source of infection, and attributable mortality of Acinetobacter
baumannii derived from patients with imipenem-resistant Acinetobacter baumannii (IRAB) bacteremia or imipenem-susceptible
Acinetobacter baumannii (ISAB) bacteremia
ST Bartual’s PubMLST
allelic profiles
CC No. of
isolates (%)
Carbapenem resistance genes VAP as a
source No. (%)
Mortality
(%)MLST
(B/P)
Tn2006
No. (%)
Tn2008
No. (%)
ISAba1eblaOXA-51
No. (%)
ISAba3eblaOXA-58eISAba3,
No. (%)
blaIMP
No. (%)
IRAB
455/2 1-87-3-2-2-83-3 455 15 (38.5) 10 (66.7) 2 (13.3) 3 (20) 0 (0) 0 (0) 13 (86.7) 13/15 (86.7)
544/2 1-87-3-2-2-97-3 455 4 (10.2) 1 (25) 2 (50) 0 (0) 0 (0) 0 (0) 3 (75) 3/4 (75)
545/2 1-12-3-2-2-104-3 545 4 (10.2) 3 (75) 0 (0) 0 (0) 0 (0) 0 (0) 3 (75) 3/4 (75)
208/2 1-3-3-2-2-97-3 92 3 (7.7) 0 (0) 1 (33.3) 0 (0) 0 (0) 0 (0) 3 (100) 1/3 (33.3)
436/2 1-3-3-2-2-103-3 92 2 (5.1) 0 (0) 0 (0) 2 (100) 0 (0) 0 (0) 2 (100) 1/2 (50)
191/2 1-3-3-2-2-94-3 92 2 (5.1) 1 (50) 1 (50) 0 (0) 0 (0) 0 (0) 1 (50) 0/2 (0)
473/2 1-3-3-2-2-99-3 92 2 (5.1) 1 (50) 0 (0) 0 (0) 0 (0) 0 (0) 2 (100) 1/2 (50)
456/217 11-65-14-20-37-83-15 456 1 (2.6) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 1 (100) 1 (100)
546/2 1-3-3-2-2-66-3 92 1 (2.6) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0)
547/2 1-3-3-2-2-157-3 92 1 (2.6) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0)
548/N1 1-15-3-2-2-157-3 d 1 (2.6) 1 (100) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 1 (100)
549/129 18-3-3-2-1-99-4 555 1 (2.6) 0 (0) 0 (0) 1 (100) 0 (0) 0 (0) 1 (100) 0 (0)
550/129 18-3-3-2-1-157-4 555 1 (2.6) 0 (0) 1 (100) 1 (100) 0 (0) 0 (0) 1 (100) 0 (0)
551/129 18-15-3-2-1-106-4 d 1 (2.6) 1 (100) 0 (0) 0 (0) 0 (0) 0 (0) 1 (100) 0 (0)
ISAB
208/2 1-3-3-2-2-97-3 92 2 (15.4) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 1 (50) 1/2 (50)
552 21-35-2-28-1-145-4 552 2 (15.4) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 2 (100) 1/2 (50)
485 33-12-59-11-32-158-5 d 1 (7.7) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0)
546/2 1-3-3-2-2-66-3 92 1 (7.7) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0)
553 21-35-2-28-1-157-4 552 1 (7.7) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 1 (100) 1/1 (100)
554 1-31-12-11-4-103-3 d 1 (7.7) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0)
679 56-100-137-7-51-99-74 d 1 (7.7) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0)
680 21-101-3-28-32-172-5 d 1 (7.7) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0)
681 1-102-59-28-1-83-45 d 1 (7.7) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0)
683 2-38-42-1-1-185-49 d 1 (7.7) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0)
MLST Z multilocus sequence typing; VAP Z ventilator-associated pneumonia; B/P Z Bartual’s PubMLST and Pasteur’s MLST.
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Table 2 Sequence types (ST), allelic profiles, clonal complex (CC), imipenem resistance genes, and attributable mortality of
Acinetobacter baumannii derived from patients with ventilator-associated pneumonia caused by imipenem-resistant A. bau-
mannii (IRAB) or imipenem-susceptible A. baumannii (ISAB)
ST (B/P) Allelic profiles CC Number of
isolates (%)
Carbapenem resistance genes Mortality
(%)Tn2006
No. (%)
Tn2008
No. (%)
ISAba1eblaOXA-51
No. (%)
ISAba3eblaOXA-58-
ISAba3 No. (%)
blaIMP
No. (%)
IRAB
455/2 1-87-3-2-2-83-3 455/2 11 (45.8) 10 (90.9) 1 (9.1) 0 (0) 0 (0) 0 (0) 3/11 (27.3)
544/2 1-87-3-2-2-97-3 455/2 4 (16.7) 4 (100) 0 (0) 0 (0) 0 (0) 0 (0) 2/4 (50)
208/2 1-3-3-2-2-97-3 92/2 2 (8.3) 1 (50) 1 (50) 0 (0) 0 (0) 0 (0) 1/2 (50)
556/N2 1-12-3-2-2-144-3 545 1 (4.2) 1 (100) 0 (0) 0 (0) 0 (0) 0 (0) 1/1 (100)
456/217 11-65-14-20-37-83-15 456 1 (4.2) 0 (0) 0 (0) 0 (0) 1 (100) 1 (100) 1/1 (100)
473/2 1-3-3-2-2-99-3 92/2 1 (4.2) 0 (0) 0 (0) 1 (100) 0 (0) 0 (0) 0 (0)
545/2 1-12-3-2-2-104-3 545/2 1 (4.2) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0)
555/129 18-3-3-2-1-144-4 555 1 (4.2) 1 (100) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0)
673/129 18-3-3-2-1-144-73 555 1 (4.2) 0 (0) 0 (0) 1 (100) 0 (0) 0 (0) 0 (0)
676/2 1-3-3-2-2-184-3 92/2 1 (4.2) 1 (100) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0)
ISAB
436 1-3-3-2-2-103-3 92 1 (16.7) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0)
556 1-12-3-2-2-144-3 545 1 (16.7) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0)
674 11-20-14-20-37-83-15 456 1 (16.7) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0)
675 11-65-14-21-37-83-15 456 1 (16.7) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0)
677 55-65-136-65-27-172-57 d 1 (16.7) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 1 (100)
678 26-99-43-20-25-83-28 d 1 (16.7) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0)
Figure 1. Population snapshot of 82 Acinetobacter baumannii isolates derived from patients in this study. Current existing clones
in Bartual’s PubMLST database analyzed using the eBURST algorithm were shown. The radial diagram reflects the predicted
evolutionary descent from the sequence type of the founder. A circle represents a sequence type, and its size corresponds to the
number of isolates. CC92 included ST208 with its derivative STs (ST191, ST436, ST473, ST546, ST547, and ST676). Novel CC455,
including ST455 and ST544, have a double-locus-variant relationship with ST92 and derived from CC92 following the evolutionary
line from ST208 to ST455. In addition to CC455, four other new clonal complexes (CC456, CC545, CC552, and CC555) descent from
ST456, ST545, ST552, and ST555 were also found and newly named by this study.
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Table 3 Comparison of clinical presentations of patients with ST455B/ST2P infections and those with non-ST455B/ST2P
infectionsa among the study population of all patients with bloodstream imipenem-resistant Acinetobacter baumannii ST2P
infections
Characteristic Patients with ST455B/ST2P
n Z 15
Patients with non-ST455B/ST2P
n Z 19
p
Demographic characteristics
Age (y) 64.8  18.1 66.6  18.0 0.930
Male 7 (46.7) 11(57.9) 0.516
Length of stay in hospital (d) 32.3  26.8 24.3  19.8 0.327
Length of stay in ICU (d) 12.1  4.3 8.8  3.0 0.014
Underlying diseases
Charlson score 3.7  2.7 4.1  3.0 0.700
Neoplastic diseaseb 7 (46.7) 11 (57.9) 0.516
Metastatic malignancyb 3 (20.0) 4 (21.1) 0.940
Cardiac disease 3 (20.0) 6 (31.6) 0.451
Cerebrovascular disease 1 (6.7) 4 (21.1) 0.264
Diabetes 5 (33.3) 1 (5.3) 0.059
Pulmonary disease 3 (20.0) 2 (10.5) 0.445
Hepatic disease 1 (6.7) 2 (10.5) 0.696
Renal disease 7 (46.7) 7 (36.8) 0.564
Peptic ulcer 1 (6.7) 5 (26.3) 0.165
Clinical severity
APACHE II score 26.6  4.7 23.0  5.0 0.040
Pitt bacteremia score 5.7  1.9 4.2  2.0 0.032
Attributable mortality 13 (86.7) 9 (47.3) 0.026
Inappropriate initial therapy 10 (66.7) 11 (57.9) 0.827
Data are presented as mean  standard deviation for continuous variables, and number of cases (%) for categorical variables.
APACHE II Z Acute Physiology and Chronic Health Evaluation II; ICU Z intensive care unit.
a Isolates of non-ST455B/ST2P are those belonging to ST2 in the Pasteur’s scheme but not ST455 in the Bartual’s scheme. They belonged
to ST544, ST545, ST208, ST436, ST191, ST473, ST546, and ST547 in the Bartual’s scheme.
b Neoplastic disease included metastatic malignancy and other primary neoplastic diseases.
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carried ISAba3 in the downstream and showed high-level
resistance to imipenem (MIC  16 mg/L). This isolate
belonged to ST456. One isolate belonging to ST456 harboredTable 4 Logistic regression analysis of risk factors for mortali
bacter baumannii infection
Characteristic Nonsurvivors
n Z 24
Survivors
n Z 15
U
O
MLST genotypes
ST455B 13 (54.2) 2 (13.3)
ST2P 22 (91.7) 13 (86.7)
Demographic characteristics
Age (y) 64.4  17.6 68.9  20.0
Male 13 (54.1) 10 (66.7)
Underlying diseases
Charlson score 3.62  2.90 3.60  2.67 1
Clinical severity
APACHE II score 24.0  5.2 22.1  4.5
Pitt bacteremia score 5.3  1.9 4.0  2.2
Inappropriate initial therapy 18 (79.2) 4 (26.7) 1
Data are presented as mean  standard deviation for continuous var
* All variables with a p value < 0.20 in the univariate analysis were
multivariate analysis. A forward stepwise selection process was utilize
therapy were statistically significant risk factors for mortality.
APACHE II Z Acute Physiology and Chronic Health Evaluation II; CI Z
Please cite this article in press as: Lee H-Y, et al., Emergence in Tai
causing bloodstream infection in critical patients, Journal of Microbiol
j.jmii.2015.04.001blaIMP-1 that offered all these isolates with high-level
resistance to imipenem as well. None of the isolates car-
ried blaOXA-40/blaOXA-24, blaIMP-2, blaVIM-1, blaVIM-2, or blaNDM-
1, blaADC, ISAba2, IS1008, or Tn2007 (ISAba4eblaOXA-23).ty of patents with bloodstream imipenem-resistant Acineto-
nivariate analysis p Multivariate analysis* p
dds ratio (95% CI) Odds ratio (95% CI)
7.68 (1.42e41.69) 0.018 11.26 (1.45e87.78) 0.021
2.75 (0.40e18.80) 0.302
0.99 (0.95e1.02) 0.456
0.59 (0.16e2.26) 0.442
.003 (0.79e1.27) 0.978
1.18 (1.02e1.37) 0.030
1.39 (0.99e1.95) 0.058
0.45 (2.31e47.30) 0.002 14.31 (2.34e87.57) 0.004
iables, and number of cases (%) for categorical variables.
considered to be included in the logistic regression model in the
d. We found that only infection by ST455 and inappropriate initial
confidence interval.
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+ MODELThere was no significant difference in the number of
isolates carrying Tn2006 between blood and sputum IRAB
(25/39 vs. 18/24, p Z 0.416). Similar results were also
found in other carbapenem resistance genes (all p > 0.05).
Clinical outcomes
Among 34 patients with ST2P infection (87.2% of IRAB), 15
patients infected by ST455B/ST2P had higher attributable
mortality (p Z 0.026), higher APACHE II score (p Z 0.040),
higher Pitt bacteremia score (p Z 0.032), and longer ICU
stay (p Z 0.014) than 19 patients with non-ST455B/ST2P
infection (Table 3).
In multivariate logistic regression analysis for mortality
of the patients, infection by ST455B and inappropriate
initial antimicrobial therapy were statistically significant
risk factors for mortality (Table 4). For IRAB bacteremia,
patients given appropriate therapy (early effective antibi-
otics administered in 2 days) had a lower mortality (31.2%)
than those given inappropriate therapy (late therapy or
therapy with ineffective agents; 82.6%; p Z 0.002). Mean
culture reporting time was 3 days.
Patients with IRAB bacteremia showed higher mortality
(26/39, 66.7%) than those with ISAB bacteremia (3/13,
23.1%; p Z 0.009). Patients with IRAB bacteremia showed
higher mortality (26/39, 66.7%) than those with only IRAB
pneumonia (8/24, 33.3%; p Z 0.018). Patients with ST455
bacteremia showed higher mortality (13/15, 86.7%) than
those with non-ST455 bacteremia (16/37, 43.2%;
p Z 0.005).
Discussion
Although Pasteur’s scheme is considered to be the gold
standard of the MLST method in typing A. baumannii,6 we
found in this study that ST455B/ST2P can only be differen-
tiated from non-ST455B/ST2P by using Bartual’s scheme.
ST455B was first reported in Taiwan, however, it has been
reported to be the predominant clone among A. baumannii
isolates collected from 12 hospitals throughout Japan.20
ST455 also appeared in southern Taiwan (C.H. Chiu, un-
published data). Since the population structure of A. bau-
mannii seems to be highly diverse,21 it is important to use
an MLST scheme with a higher level of resolution to identify
any tiny but significant difference. In our study, nine
different STs (ST455, ST544, ST545, ST208, ST436, ST191,
ST473, ST546, and ST547) by Bartual’s scheme could not be
differentiated by Pasteur’s scheme and thus all nine
different STP belonged to ST2B. However, ST455B/ST2P
infection showed a significantly higher attributable mor-
tality than non-ST455B/ST2P (Table 3). The important clin-
ical difference can only be found using Bartual’s scheme
rather than Pasteur’s scheme. All ST455B/ST2P isolates
were collected from patients in ICUs in our hospital during a
12-month period. We have observed no temporal or
geographic association among these isolates. No outbreak
was found. By contrast, PFGE genotypes 1e7 could only be
differentiated by different MLST genotypes using Bartual’s
scheme rather than Pasteur’s scheme.
Although Bartual’s scheme was an important MLST
method for genotyping A. baumannii worldwide,4,6 no dataPlease cite this article in press as: Lee H-Y, et al., Emergence in Tai
causing bloodstream infection in critical patients, Journal of Microbiolo
j.jmii.2015.04.001were found by this method in Taiwan. Fifteen isolates in
2006 were analyzed using only Pasteur’s scheme in the
Taiwan Surveillance of Antimicrobial Resistance study and
all belonged to ST2P.22 In another study, a total of 19 MLST
types defined by Pasteur’s scheme were found among the
87 isolates examined in 2010.23 The predominant MLST
genotype, ST2P, was identified in 42 isolates and ST129P in
25 isolates.23 Likewise, ST2P and ST129P were the major
sequence types in isolates in this study. Again, Bartual’s
scheme has never been used in previous studies, and
identification of novel, clinically significant STs by Bartual’s
scheme was not possible in previous as well as current
studies.22,23
Most isolates in this study belonged to CC92B/CC2P,
which is currently the most prevalent clonal complex
worldwide.6,24 Currently, most clinical isolates in Asia, USA,
and Australia belong to CC92 and carried blaOXA-23.
25e29
AbaR4-type resistance islands that carried blaOXA-23 have
been detected in IRAB isolates from most Asian countries.25
In China, ST92 was the most prevalent clone and was found
in every province of the country.26,27 It is apparent that the
reason for the rapidly increasing carbapenem resistance in
China was the wide dissemination of imipenem-resistant,
blaOXA-23-like-producing CC92, especially ST92, ST75, and
ST138.27 By contrast, carbapenem-susceptible isolates in
China had a more diverse genetic background.27 In USA,
ST122 and ST208 are the most common and were found in
four of the six hospitals surveyed in previous studies.28,29
Carbapenemase-encoding genes blaOXA-23 and/or I SAba1-
blaOXA-51-like were present among the majority of these
isolates. First reported in Pittsburgh, St Louis, Los Angeles,
and Las Vegas in the USA in 2008e2009,28 ST208 was the
founder of our isolates belonging to CC92. ST208 was also
found in Denmark,30 Egypt, and China (http://pubmlst.org/
abaumannii/). In Australia, most clinical isolates of A.
baumannii also belong to ST92 and carry blaOXA-23.
24
IRAB appears to be more diverse in South America.31e33
However, blaOXA-23-like gene and AbaR-type genomic islands
widely distributed in CC92 were also found in different CCs.
In Brazil, CC104, CC109, and CC113 were found as pre-
dominant clones.33 Most IRAB isolates (72%) carried blaOXA-
23-like gene in Brazil.
31 CC104 and CC113 were also found
common in Argentina. AbaR-type genomic islands have
been detected in most multidrug resistant A. baumannii
isolates (36/51) in Argentina, Uruguay, and Chile since
1986.32 CC113, CC103, and ST25 were the major clones in
Buenos Aires and Rosario and most of these clones carried
blaOXA-23-like.
33
We identified 26 novel STB and five novel CCB in this
study. Novel ST455B, contributing to 38.5% of IRAB
bacteremia, resulted in 86.7% attributable mortality,
which was much higher than previously reported.19,34 A
possible explanation for the successful spread of ST455 in
the hospitals is that they have a selective advantage over
other strains. Antimicrobial resistance is one such advan-
tage, and we found that all ST455 isolates showed high
imipenem resistance (MIC > 16 mg/L) and also resistance
to all other tested antibiotics except colistin and tigecy-
cline. In addition to 33.3% of isolates carrying Tn2008 or
ISAba1eblaOXA-51, 66.7% of ST455 bloodstream isolates
carried Tn2006 in an AbaR4-type resistance island. It is
difficult to give effective antibiotics for treating ST455wan of novel imipenem-resistant Acinetobacter baumannii ST455
gy, Immunology and Infection (2015), http://dx.doi.org/10.1016/
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+ MODELinfection in the 2 days before culture reporting (mean, 3
days). No administration of appropriate drugs in time
apparently resulted in high mortality among patients
infected by ST455. This clone might become a threat to
public health because higher attributable mortality, higher
APACHE II score, and higher Pitt bacteremia score were
found from patients with ST455B/ST2P infection. Increased
virulence of this clone deduced from this result needs
further study.
The majority of IRAB ST455 isolates showed a common
imipenem resistance genetic determinant, ISAba1eblaOXA-
23eISAba1 (Tn2006), located in an AbaR4-type resistance
island. Our previous study indicated that in Taiwan this
transposon had become the most common carbapenem
resistance gene in A. baumannii since 2009 and has
replaced ISAba1eblaOXA-51, the predominant resistance
mechanism from 1993 to 2007.17,19
ST455 bacteremia appeared to originate from VAP based
on three findings of this study: firstly, > 85% of ST455
bacteremia had a primary source of VAP; secondly, no sig-
nificant difference was found in the distribution of STs and
carbapenemase genes between blood isolates from
bacteremic patients and sputum isolates from patients with
VAP; and thirdly, all three paired isolates from blood and
sputum of the same patients showed the same MLST and
PFGE genotype, including two patients infected by ST455
(PFGE type 1) and one by ST544 (PFGE type 2).
In conclusion, A. baumannii has become the most com-
mon pathogen for nosocomial bloodstream infection in ICUs
in Taiwan since 2009.19 ST455B/ST2P, the predominant
clone of IRAB identified in this study, has been posing a
significant threat to patients’ health and has the potential
to cause a regional or global spread, given its highly path-
ogenic and resistant nature. Continued surveillance is
necessary. It is also important to detect and use effective
drugs to treat ST455B/ST2P infection earlier at the stage of
VAP rather than in the bacteremic stage to decrease
mortality.
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